Quarterly Earnings

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

With a major earnings call set for Feb. 23, Lincoln Educational Services' 2025 results will reveal if its aggressive expansion meets soaring market demand.

Havas reports 3.1% organic growth, driven by its Converged.AI platform and a series of key acquisitions, positioning it as a tech-forward industry leader.

Following a year of robust earnings and a 10% dividend hike, Great-West Lifeco's CEO is set to detail the firm's future plans in a key investor chat.

As KP Tissue prepares to release Q4 2025 results, all eyes are on Kruger Products' performance after a year of major strategic investments and expansion.

LiveRamp adds Uber's ad chief and retail media architect Kristi Argyilan to its board, signaling a major push into the future of AI-driven commerce media.

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Fortrea splits key roles, dedicating its CMO to scientific strategy and hiring a new president for clinical pharmacology in a bold post-spin-off move.

As firms face a data deluge and new rules, Normative's new service outsources the heavy lifting of carbon accounting for overstretched teams.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

Essent Group boosts its dividend after a strong 2025, returning $700M to shareholders while making a strategic leap into the global P&C reinsurance market.

Magna beat Q4 expectations and raised its dividend, but a $591M tech impairment and looming Ford recall costs paint a complex picture for the auto giant.

Vitalist reports soaring losses and a $6.4M debt surge, raising 'going concern' alarms. Can its new Reebok smartwatches and VitalOS™ platform save it?

With strong financials and a focus on tech, Allegion's CEO will outline the security giant's long-term strategy for a digitally connected world.

With top executives set for major conferences, investors eye Mastercard's playbook for commercial payments and Americas growth amid fierce competition.